CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jan. 02, 2026	Jan. 03, 2025
Current assets:
Cash and cash equivalents	$ 482,488	$ 217,374
Marketable securities	576,603	893,902
Trade receivables, net	286,916	265,437
Inventory	21,686	22,388
Prepaid expenses and other current assets	75,596	68,478
Total current assets	1,443,289	1,467,579
Non-current marketable securities	603,603	637,291
Property and equipment, net	98,960	119,391
Deferred tax assets, net	292,582	420,027
Goodwill	63,684	63,684
Right-of-use assets and other non-current assets	342,305	239,718
Total assets	2,844,423	2,947,690
Current liabilities:
Accounts payable	29,623	38,191
Accrued compensation and benefits	102,218	109,830
Accrued clinical trial liabilities	65,742	57,976
Rebates and fees due to customers	59,896	62,376
Accrued collaboration liabilities	22,783	40,384
Other current liabilities	125,382	95,012
Total current liabilities	405,644	403,769
Non-current operating lease liabilities	173,038	190,823
Other non-current liabilities	104,422	108,895
Total liabilities	683,104	703,487
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued	0	0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 262,483 and 281,732 at December 31, 2025 and 2024, respectively	262	282
Additional paid-in-capital	2,234,411	2,343,915
Accumulated other comprehensive income (loss)	3,476	(1,347)
Accumulated deficit	(76,830)	(98,647)
Total stockholders’ equity	2,161,319	2,244,203
Total liabilities and stockholders’ equity	$ 2,844,423	$ 2,947,690